
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3366145/publications.pdf Version: 2024-02-01



KOEN VAN DE VIIVER

#	Article	IF	CITATIONS
1	Ovotesticular Difference of Sex Development: Genetic Background, Histological Features, and Clinical Management. Hormone Research in Paediatrics, 2023, 96, 180-189.	1.8	7
2	Extrauterine Mesonephric-like Neoplasms. American Journal of Surgical Pathology, 2022, 46, 124-133.	3.7	26
3	Shallow whole-genome sequencing: a useful, easy to apply molecular technique for CNA detection on FFPE tumor tissue—a glioma-driven study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 677.	2.8	0
4	Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!. Pathology Research and Practice, 2022, 231, 153772.	2.3	4
5	Interâ€observer agreement for the histological diagnosis of invasive lobular breast carcinoma. Journal of Pathology: Clinical Research, 2022, 8, 191-205.	3.0	19
6	Effect of <scp>HIPEC</scp> according to <scp>HRD</scp> / <scp><i>BRCA</i>wt</scp> genomic profile in stage <scp>III</scp> ovarian cancer: Results from the phase <scp>III OVHIPEC</scp> trial. International Journal of Cancer, 2022, 151, 1394-1404.	5.1	15
7	Distinct Transcriptional Programs in Ascitic and Solid Cancer Cells Induce Different Responses to Chemotherapy in High-Grade Serous Ovarian Cancer. Molecular Cancer Research, 2022, 20, 1532-1547.	3.4	2
8	Serous Tubal Intraepithelial Carcinoma–Like and Pagetoid Tubal Metastasis of an Ovarian Large Cell Neuroendocrine Carcinoma: Peculiar Metastatic Growth Patterns of a Rare Tumor. International Journal of Surgical Pathology, 2021, 29, 281-283.	0.8	3
9	Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study. Annals of Surgical Oncology, 2021, 28, 3243-3253.	1.5	48
10	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. Human Pathology, 2021, 109, 80-91.	2.0	22
11	Mesonephric-Like Adenocarcinoma of the Endometrium: Diagnostic Advances to Spot This Wolf in Sheep's Clothing. A Review of the Literature. Journal of Clinical Medicine, 2021, 10, 698.	2.4	23
12	Histological interpretation of differentiated vulvar intraepithelial neoplasia (dVIN) remains challenging—observations from a bi-national ring-study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 305-315.	2.8	13
13	Embryonal rhabdomyosarcoma of the uterine corpus: a clinicopathological and molecular analysis of 21 cases highlighting a frequent association with DICER1 mutations. Modern Pathology, 2021, 34, 1750-1762.	5.5	21
14	Optical tissue measurements of invasive carcinoma and ductal carcinoma in situ for surgical guidance. Breast Cancer Research, 2021, 23, 59.	5.0	6
15	A rare but devastating cause of twin loss in a nearâ€term pregnancy highlighting the features of severe SARSâ€CoVâ€2 placentitis. Histopathology, 2021, 79, 674-676.	2.9	13
16	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Modern Pathology, 2021, 34, 2130-2140.	5.5	14
17	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. Acta Clinica Belgica, 2021, , 1-13.	1.2	4
18	High-Resolution 18F-FDG PET/CT for Assessing Three-Dimensional Intraoperative Margins Status in Malignancies of the Head and Neck, a Proof-of-Concept. Journal of Clinical Medicine, 2021, 10, 3737.	2.4	13

#	Article	IF	CITATIONS
19	Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth. , 2021, 9, e003623.		12
20	Approach to the Virilizing Girl at Puberty. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1530-1539.	3.6	7
21	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Modern Pathology, 2020, 33, 354-366.	5.5	25
22	Female adnexal tumors of probable Wolffian origin: morphological, immunohistochemical, and molecular analysis of 15 cases. Modern Pathology, 2020, 33, 734-747.	5.5	23
23	Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer. International Journal of Gynecological Pathology, 2020, 39, 420-427.	1.4	6
24	Inflammatory Myofibroblastic Tumor of the Uterus. American Journal of Surgical Pathology, 2020, 44, 1441-1449.	3.7	29
25	Splenic 18F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer. Gynecologic Oncology, 2020, 159, 335-343.	1.4	10
26	Feasibility study on pre or postoperative accelerated radiotherapy (POP-ART) in breast cancer patients. Pilot and Feasibility Studies, 2020, 6, 154.	1.2	4
27	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer, 2020, 6, 15.	5.2	16
28	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine, 2020, 17, e1003111.	8.4	25
29	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	5.2	106
30	The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 535-544.	2.8	7
31	Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. European Journal of Cancer, 2020, 127, 240-250.	2.8	21
32	Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment. International Journal of Cancer, 2020, 147, 554-564.	5.1	14
33	Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma. Scientific Reports, 2020, 10, 6688.	3.3	14
34	Uncovering the immune-modulating role of anti-RANKL therapy for cervical cancer: Preliminary results Journal of Clinical Oncology, 2020, 38, e18028-e18028.	1.6	0
35	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Research, 2019, 21, 90.	5.0	81
36	Ultrastaging of sentinel lymph nodes in gynecological cancer: Repeating the story of breast cancer? Letter to the editor, Reply to Cibula D, McCluggage WG. Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions. Gynecol Oncol 2019;152:202–7. Gynecologic Oncology Reports, 2019, 29, 130-131.	0.6	2

#	Article	IF	CITATIONS
37	Imaging depth variations in hyperspectral imaging: Development of a method to detect tumor up to the required tumorâ€free margin width. Journal of Biophotonics, 2019, 12, e201900086.	2.3	15
38	Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989–2015. European Journal of Cancer, 2019, 118, 97-104.	2.8	16
39	Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial. Journal of Clinical Oncology, 2019, 37, 2041-2050.	1.6	39
40	The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype. Journal of the National Cancer Institute, 2019, 111, 709-718.	6.3	40
41	Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology, 2019, 89, 90-98.	2.0	5
42	Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. Histopathology, 2019, 75, 128-136.	2.9	32
43	Trends in incidence, treatment and survival of borderline ovarian tumors in the Netherlands: a nationwide analysis. Acta Oncológica, 2019, 58, 983-989.	1.8	18
44	Measuring the depth of invasion in vulvar squamous cell carcinoma: interobserver agreement and pitfalls. Histopathology, 2019, 75, 413-420.	2.9	9
45	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature Medicine, 2019, 25, 920-928.	30.7	589
46	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer, 2019, 120, 1037-1044.	6.4	10
47	Outcome of surgery in advanced ovarian cancer varies between geographical regions; opportunities for improvement in The Netherlands. European Journal of Surgical Oncology, 2019, 45, 1425-1431.	1.0	8
48	Hyperspectral Imaging for Resection Margin Assessment during Cancer Surgery. Clinical Cancer Research, 2019, 25, 3572-3580.	7.0	60
49	SATB2 is Consistently Expressed in Squamous Morules Associated With Endometrioid Proliferative Lesions and in the Stroma of Atypical Polypoid Adenomyoma. International Journal of Gynecological Pathology, 2019, 38, 397-403.	1.4	25
50	The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review. Gynecologic Oncology, 2019, 153, 445-451.	1.4	22
51	The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer. Gynecologic Oncology, 2019, 153, 562-567.	1.4	7
52	Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS. American Journal of Surgical Pathology, 2019, 43, 1574-1582.	3.7	17
53	Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial. Obstetrical and Gynecological Survey, 2019, 74, 592-593.	0.4	1
54	Gene Promoter Methylation in Endometrial Carcinogenesis. Pathology and Oncology Research, 2019, 25, 659-667.	1.9	8

#	Article	IF	CITATIONS
55	Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multi-institutional Study. International Journal of Gynecological Pathology, 2019, 38, 205-215.	1.4	20
56	Influence of neoadjuvant chemotherapy on diffuse reflectance spectra of tissue in breast surgery specimens. Journal of Biomedical Optics, 2019, 24, 1.	2.6	1
57	Method for coregistration of optical measurements of breast tissue with histopathology: the importance of accounting for tissue deformations. Journal of Biomedical Optics, 2019, 24, 1.	2.6	9
58	Broadband hyperspectral imaging for breast tumor detection using spectral and spatial information. Biomedical Optics Express, 2019, 10, 4496.	2.9	43
59	MRI of Paratubal Borderline Serous Tumor. Journal of the Belgian Society of Radiology, 2019, 103, 48.	0.3	0
60	Abstract 4879: Poor outcome in hypoxic endometrial carcinoma is related to vascular density. , 2019, , .		0
61	Abstract 751: Ductal carcinomain situof the breast: Cancer precursor or not. , 2019, , .		0
62	Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma <i>In Situ</i> —A Nested Case–Control Study. Clinical Cancer Research, 2018, 24, 3593-3601.	7.0	30
63	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. New England Journal of Medicine, 2018, 378, 230-240.	27.0	1,012
64	Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. International Journal of Gynecological Cancer, 2018, 28, 514-523.	2.5	43
65	Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. Journal of Histochemistry and Cytochemistry, 2018, 66, 67-83.	2.5	92
66	Uterine PEComas. American Journal of Surgical Pathology, 2018, 42, 1370-1383.	3.7	114
67	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i> -like status, tumor-infiltrating immune cells and survival. Oncolmmunology, 2018, 7, e1509820.	4.6	80
68	Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment). Breast, 2018, 40, 76-81.	2.2	29
69	Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecologic Oncology, 2018, 150, 446-450.	1.4	42
70	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Obstetrical and Gynecological Survey, 2018, 73, 280-281.	0.4	2
71	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative. Clinical Cancer Research, 2017, 23, 1274-1285.	7.0	30
72	Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Müllerian origin from gastrointestinal cancer. Cancer Cytopathology, 2017, 125, 197-204.	2.4	4

#	Article	IF	CITATIONS
73	Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 655-664.	2.8	29
74	Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. Breast Cancer Research and Treatment, 2017, 164, 133-138.	2.5	12
75	The histophysiology and pathophysiology of the peritoneum. Tissue and Cell, 2017, 49, 95-105.	2.2	139
76	Incidence of lymph node metastases in clinical earlyâ€stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study. BJOC: an International Journal of Obstetrics and Gynaecology, 2017, 124, 486-494.	2.3	13
77	Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€"Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Cenitourinary Carcinomas, and Primary Brain Tumors, Advances in Anatomic Pathology, 2017, 24, Assessing Tumor-infiltrating Lymphocytes in Solid Tumors. A Practical Review for Pathologists and	4.3	530
78	Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic	4.3	469
79	Pathology, 2017, 24, 235-251. Changes in the Extracellular Matrix Are Associated With the Development of Serous Tubal Intraepithelial Carcinoma Into High-Grade Serous Carcinoma. International Journal of Gynecological Cancer, 2017, 27, 1072-1081.	2.5	11
80	Reproducibility of measurement of myometrial invasion in endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 63-68.	2.8	11
81	Overcoming sampling depth variations in the analysis of broadband hyperspectral images of breast tissue (Conference Presentation). , 2017, , .		0
82	Abstract 4738: Risk of ipsilateral invasive breast cancer after DCIS: a comparison of primary DCIS and subsequent invasive disease by morphological and immunohistochemical analysis. , 2017, , .		0
83	Abstract 5612: Cancer-immune interactions in luminal breast cancers:PI3KCAmutations, PI3K/AKT/mTOR activation and tumor-infiltrating lymphocytes. , 2017, , .		Ο
84	Abstract 575: PD-L1 positive tumor-infiltrating lymphocytes and mutational load in breast cancer. , 2017, , .		0
85	Using DRS during breast conserving surgery: identifying robust optical parameters and influence of inter-patient variation. Biomedical Optics Express, 2016, 7, 5188.	2.9	17
86	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	5.5	230
87	L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. British Journal of Cancer, 2016, 115, 716-724.	6.4	76
88	Difficulties with diagnosis of malignancies in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 33, 19-32.	2.8	50
89	Is Urinary Lipoarabinomannan the Result of Renal Tuberculosis? Assessment of the Renal Histology in an Autopsy Cohort of Ugandan HIV-Infected Adults. PLoS ONE, 2015, 10, e0123323.	2.5	36
90	Germ-line variants identified by next generation sequencing in a panel of estrogen and cancer associated genes correlate with poor clinical outcome in Lynch syndrome patients. Oncotarget, 2015, 6, 41108-41122.	1.8	5

#	Article	IF	CITATIONS
91	Diagnostic Performance of Dedicated Axillary T2- and Diffusion-weighted MR Imaging for Nodal Staging in Breast Cancer. Radiology, 2015, 275, 345-355.	7.3	53
92	Significance of Lymphovascular Space Invasion in Uterine Serous Carcinoma. International Journal of Gynecological Pathology, 2015, 34, 47-56.	1.4	29
93	Accuracy of Lipoarabinomannan and Xpert MTB/RIF Testing in Cerebrospinal Fluid To Diagnose Tuberculous Meningitis in an Autopsy Cohort of HIV-Infected Adults. Journal of Clinical Microbiology, 2015, 53, 2667-2673.	3.9	27
94	Practice of percutaneous needle autopsy; a descriptive study reporting experiences from Uganda. BMC Clinical Pathology, 2014, 14, 44.	1.8	20
95	Angiosarcomas of Primary Gynecologic Origin: A Clinicopathologic Review and Quantitative Analysis of Survival. International Journal of Gynecological Cancer, 2014, 24, 4-12.	2.5	41
96	Needle Autopsy to Establish the Cause of Death in HIV-Infected Hospitalized Adults in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 169-176.	2.1	30
97	Aggressive Behavior and Poor Prognosis of Endometrial Stromal Sarcomas With YWHAE-FAM22 Rearrangement Indicate the Clinical Importance to Recognize This Subset. International Journal of Gynecological Cancer, 2014, 24, 1616-1622.	2.5	23
98	The majority of metachronous CIN1 and CIN3 lesions are caused by different human papillomavirus genotypes, indicating that the presence of CIN1 seems not to determine the risk for subsequent detection of CIN3. Human Pathology, 2014, 45, 221-226.	2.0	6
99	Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis. Gynecologic Oncology, 2014, 132, 372-376.	1.4	4
100	The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients. Breast Cancer Research and Treatment, 2014, 143, 469-476.	2.5	21
101	The Detection of Sentinel Nodes in Ovarian Cancer: A Feasibility Study. Journal of Nuclear Medicine, 2014, 55, 1799-1804.	5.0	45
102	A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Research, 2013, 15, R29.	5.0	55
103	Sentinel node in ovarian cancer: study protocol for a phase 1 study. Trials, 2013, 14, 47.	1.6	7
104	Molecular biomarkers in cervical cancer diagnosis: a critical appraisal. Expert Opinion on Medical Diagnostics, 2013, 7, 365-377.	1.6	30
105	Oncogene alterations in endometrial carcinosarcomas. Human Pathology, 2013, 44, 852-859.	2.0	27
106	Type I and II Endometrial Cancers: Have They Different Risk Factors?. Journal of Clinical Oncology, 2013, 31, 2607-2618.	1.6	613
107	Correlation of tumor size with other prognostic factors in uterine serous carcinoma: A large multi-institutional study. Cynecologic Oncology, 2013, 128, 316-321.	1.4	7
108	Clinical and Pathologic Characteristics of Serous Carcinoma Confined to the Endometrium. International Journal of Gynecological Pathology, 2013, 32, 181-187.	1.4	30

#	Article	IF	CITATIONS
109	Overexpression of 17β-Hydroxysteroid Dehydrogenase Type 1 Increases the Exposure of Endometrial Cancer to 17β-Estradiol. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E591-E601.	3.6	62
110	Paired-box gene 2 is down-regulated in endometriosis and correlates with low epidermal growth factor receptor expression. Human Reproduction, 2012, 27, 1676-1684.	0.9	9
111	Abstract 1029: The association of body mass index with risk of endometrial cancer subtypes: Pooled analysis in E2C2. , 2012, , .		0
112	Neoplastic transformation of endocervicosis into an extraovarian mucinous cystadenocarcinoma. Human Pathology, 2011, 42, 743-748.	2.0	12
113	Re: Post-coital vaginal douching is risky for non-regression of low-grade squamous intraepithelial lesion of the cervix. Gynecologic Oncology, 2011, 122, 202-203.	1.4	1
114	Microâ€RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcoma. Journal of Pathology, 2011, 223, 72-80.	4.5	194
115	Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors. Modern Pathology, 2011, 24, 463-470.	5.5	29
116	Adenocarcinoma of the Fetal Lung-type Metastatic to the Ovary. International Journal of Gynecological Pathology, 2010, 29, 339-340.	1.4	7
117	Expression of aberrantly glycosylated Mucinâ€l in ovarian cancer. Histopathology, 2010, 57, 597-606.	2.9	60
118	Customized Computed Tomography-Based Boost Volumes in Breast-Conserving Therapy: Use of Three-Dimensional Histologic Information for Clinical Target Volume Margins. International Journal of Radiation Oncology Biology Physics, 2009, 75, 757-763.	0.8	26
119	Miscellaneous Pseudotumors and Mesenchymal Tumors of the Female Genital Tract. Surgical Pathology Clinics, 2009, 2, 755-783.	1.7	0
120	Unsuccessful resuscitation of a preterm infant due to a pneumothorax and a masked tension pneumopericardium. Resuscitation, 2008, 78, 236-239.	3.0	16
121	Ventricular thrombi with pulmonary and systemic embolization. Canadian Journal of Cardiology, 2008, 24, e92.	1.7	3
122	Expression and localization of CHODLΔE/CHODLfΔE, the soluble isoform of chondrolectin. Cell Biology International, 2007, 31, 1323-1330.	3.0	5
123	The host's genetic background determines the extent of angiogenesis induced by schistosome egg antigens. Acta Tropica, 2006, 99, 243-251.	2.0	11
124	LacdiNAc- and LacNAc-containing glycans induce granulomas in an in vivo model for schistosome egg-induced hepatic granuloma formation. Glycobiology, 2006, 16, 237-243.	2.5	44
125	Glycans of Schistosoma mansoni and keyhole limpet haemocyanin induce hepatic granulomas in vivo. International Journal for Parasitology, 2004, 34, 951-961.	3.1	31
126	Discrimination between the anti-monomeric and the anti-multimeric Lewis X response in murine schistosomiasis. Microbes and Infection, 2004, 6, 1125-1132.	1.9	24

#	Article	IF	CITATIONS
127	Circulating levels of the neuropeptide hormone somatostatin may determine hepatic fibrosis in Schistosoma mansoni infections. Acta Tropica, 2004, 90, 191-203.	2.0	12
128	Schistosomal granuloma modulation. Parasitology Research, 1999, 85, 905-909.	1.6	7
129	Transforming growth factor-β, basement membrane components and heparan sulphate proteoglycans in experimental hepatic schistosomiasis mansoni. Cell and Tissue Research, 1998, 292, 101-106.	2.9	18
130	Morphometrical and immunopathological dissection of the hepatic <i>Schistosoma haematobium</i> granuloma in the murine host. Parasite, 1998, 5, 299-306.	2.0	4